Induction of LXR markers by T0901317 on CD14+ and CD14− cells among PBMCs.

<p>Isolated PBMCs were treated with DMSO or 10 µM T0901317 for 24 or 48 hours and CD226, CD244 or CD82 cell surface expression was evaluated by flow cytometry. <b>A:</b> Dot plot representing CD14− and CD14+ selected populations. <b>B:</b> CD226, CD244 or CD82 on CD14− cells. Right panel, representative histograms. Ig: control immunoglobulin; Ab: specific antibody. Left panel, MFI in LXR agonist- and DMSO- treated cells. Each bar is the mean ± S.E.M. of 4 independent experiments using cells from 4 distinct healthy donors. <b>C:</b> CD226, CD244 or CD82 on CD14+ cells. Right panel, representative histograms. Ig: control immunoglobulin; Ab: specific antibody. Left panel, MFI in LXR agonist- and DMSO- treated cells. Each bar is the mean ± S.E.M. of 4 independent experiments. Values are set at 1 in the DMSO conditions. * : significantly different from DMSO treatment (P<0.05 Wilcoxon T test). <b>D:</b> MFI in LXR agonist- and DMSO- treated PBMCswith or without 22-S-OH cholesterol added. Each bar is the mean ± S.E.M. of 3 independent experiments using CD14+ gated PBMCs from 3 distinct healthy donors. Values are set at 1 in the DMSO conditions. *: significantly different from DMSO treatment (P<0.05 Wilcoxon T test); †: significantly different from vehicle only conditions (P<0.05 Wilcoxon T test).